{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:54:57Z","timestamp":1793253297639,"version":"4.5.0"},"reference-count":32,"publisher":"BMJ","issue":"10","funder":[{"DOI":"10.13039\/501100005416","name":"the Norwegian Research Council","doi-asserted-by":"crossref","award":["322176"],"award-info":[{"award-number":["322176"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the National Science and Technology Council","award":["113-2314-B-002-167-MY3"],"award-info":[{"award-number":["113-2314-B-002-167-MY3"]}]},{"name":"the Central Denmark Region","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100019563","name":"the Danish Epilepsy Association","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100019563","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Trond Mohn Research Foundation","award":["TMF2024TMT03"],"award-info":[{"award-number":["TMF2024TMT03"]}]},{"name":"the NRC Centres for Clinical Treatment Research scheme","award":["328615"],"award-info":[{"award-number":["328615"]}]},{"name":"ALF Medicine Stockholm","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"the Independent Research Fund Denmark","award":["4308-00142B"],"award-info":[{"award-number":["4308-00142B"]}]},{"DOI":"10.13039\/501100003554","name":"the Lundbeck Foundation","doi-asserted-by":"crossref","award":["R400-2022-1205"],"award-info":[{"award-number":["R400-2022-1205"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009708","name":"The Novo Nordisk Foundation","doi-asserted-by":"crossref","award":["NNF16OC0019126"],"award-info":[{"award-number":["NNF16OC0019126"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009708","name":"The Novo Nordisk Foundation","doi-asserted-by":"crossref","award":["NNF22OC0075033"],"award-info":[{"award-number":["NNF22OC0075033"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2026,4,15]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the association of paternal use of valproate during spermatogenesis compared with paternal use of lamotrigine or levetiracetam on offspring risk of neurodevelopmental disorders (NDDs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligibility criteria: observational, peer-reviewed studies reporting neurodevelopmental outcomes of children exposed to paternal monotherapy use of valproate vs lamotrigine or levetiracetam during spermatogenesis.<\/jats:p>\n                    <jats:p>Information sources: the databases PubMed, Embase, Cochrane Library and Web of Science were systematically searched from January 1995 to October 2025.<\/jats:p>\n                    <jats:p>\n                      Synthesis of results and risk of bias: a random-effects model was used to estimate pooled HRs and 95%\u2009CI, with heterogeneity assessed using I\n                      <jats:sup>2<\/jats:sup>\n                      statistic for any NDD.\n                    <\/jats:p>\n                    <jats:p>We present a meta-analysis of observational, peer-reviewed studies reporting neurodevelopmental outcomes of children exposed to paternal monotherapy use of valproate versus lamotrigine or levetiracetam during spermatogenesis. Given the major regulatory implications of paternal valproate safety, the recent emergence of new population-based data, and the expectation of further large studies, we designed this work as a living systematic review and meta-analysis that will be updated as new eligible evidence becomes available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified three eligible studies based on data from (1) Norway and Sweden, (2) Norway and Taiwan and (3) Denmark. As two studies included Norwegian data, their results are referred to as \u2018Norway 1\u2019 and \u2018Norway 2\u2019 for clarity. In the meta-analysis of data from Denmark, Sweden and Norway 1, the pooled HR of offspring NDDs was 1.05 (95% CI 0.87 to 1.27; I\n                      <jats:sup>2<\/jats:sup>\n                      =0.0%), and in meta-analysis of data from Denmark, Sweden and Norway 2, it was 1.03 (95% CI 0.85 to 1.24; I\n                      <jats:sup>2<\/jats:sup>\n                      =0.0%).\n                    <\/jats:p>\n                    <jats:p>\n                      In the meta-analysis including Taiwan, Denmark, Sweden and Norway 1, the pooled HR was 1.06 (95% CI 0.88 to 1.27; I\n                      <jats:sup>2<\/jats:sup>\n                      =0.0%), and when including data from Taiwan, Denmark, Sweden and Norway 2, the pooled HR was 1.04 (95% CI 0.87 to 1.25; I\n                      <jats:sup>2<\/jats:sup>\n                      =0.0%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this living meta-analysis, we found no evidence that paternal exposure to valproate compared with lamotrigine\/levetiracetam during spermatogenesis was associated with increased risk of NDDs in offspring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2026-338454","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:45:12Z","timestamp":1778582712000},"page":"890-898","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Risk of neurodevelopmental disorders associated with paternal use of valproate during spermatogenesis: a living meta-analysis\u2014version 1"],"prefix":"10.1136","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9385-6435","authenticated-orcid":false,"given":"Jakob","family":"Christensen","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University, Aarhus, Denmark"},{"name":"Department of Neurology, Aarhus University Hospital, Affiliated Member of Epi-CARE, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6282-2614","authenticated-orcid":false,"given":"Betina B","family":"Trabjerg","sequence":"additional","affiliation":[{"name":"National Centre for Register-Based Research, Department of Public Health, Aarhus University, Aarhus, Denmark"},{"name":"Centre for Integrated Register-based Research (CIRRAU), Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4853-4434","authenticated-orcid":false,"given":"Marleen M H J","family":"van Gelder","sequence":"additional","affiliation":[{"name":"PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8095-2965","authenticated-orcid":false,"given":"Lin-Chieh","family":"Meng","sequence":"additional","affiliation":[{"name":"PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway"},{"name":"Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"},{"name":"Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsi-Yu","family":"Lai","sequence":"additional","affiliation":[{"name":"Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan"},{"name":"Health Data Research Center, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-0978","authenticated-orcid":false,"given":"Jannicke","family":"Igland","sequence":"additional","affiliation":[{"name":"Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway"},{"name":"Department of Neurology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1273-0110","authenticated-orcid":false,"given":"Neda","family":"Razaz","sequence":"additional","affiliation":[{"name":"Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torbj\u00f6rn","family":"Tomson","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, and Department of Neurology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marte-Helene","family":"Bj\u00f8rk","sequence":"additional","affiliation":[{"name":"Department of Neurology, Haukeland University Hospital, Bergen, Norway"},{"name":"Norwegian Center for Headache Research (NorHead), Department of Clinical Medicine, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei-Yuan","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan"},{"name":"Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6361-2918","authenticated-orcid":false,"given":"Hedvig M E","family":"Nordeng","sequence":"additional","affiliation":[{"name":"PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway"},{"name":"Department of Child Health and Development, Norwegian Institute of Public Health, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Werenberg","family":"Dreier","sequence":"additional","affiliation":[{"name":"National Centre for Register-Based Research, Department of Public Health, Aarhus University, Aarhus, Denmark"},{"name":"Centre for Integrated Register-based Research (CIRRAU), Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"2026091402101032000_97.10.890.1","unstructured":"The European Medicines Agency\u2019s Pharmacovigilance Risk Assessment Committee (PRAC) . Potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines: PRAC recommends precautionary measures. Available: https:\/\/www.ema.europa.eu\/en\/news\/potential-risk-neurodevelopmental-disorders-children-born-men-treated-valproate-medicines-prac-recommends-precautionary-measures"},{"key":"2026091402101032000_97.10.890.2","unstructured":"IQVIA . A post-authorisation safety study (PASS) to evaluate the paternal exposure to valproate and the risk of neurodevelopmental disorders including autism spectrum disorder as well as congenital abnormalities in offspring - a population-based retrospective study (Corrigendum to the Final Report). Available: https:\/\/www.ema.europa.eu\/en\/documents\/other\/valproate-paternal-exposure-valproate-corrigendum-final-report_en.pdf"},{"key":"2026091402101032000_97.10.890.3","unstructured":"IQVIA . A post-authorisation safety study (PASS) to evaluate the paternal exposure to valproate and the risk of neurodevelopmental disorders including autism spectrum disorder as well as congenital abnormalities in offspring - a population-based retrospective study (addendum). Available: https:\/\/www.ema.europa.eu\/en\/documents\/other\/valproate-paternal-exposure-valproate-addendum_en.pdf"},{"key":"2026091402101032000_97.10.890.4","unstructured":"IQVIA . A post-authorisation safety study (pass) to evaluate the paternal exposure to valproate and the risk of neurodevelopmental disorders including autism spectrum disorder as well as congenital abnormalities in offspring - a population-based retrospective study (Final Report). Available: https:\/\/www.ema.europa.eu\/en\/documents\/other\/valproate-paternal-exposure-valproate-final-report_en.pdf"},{"key":"2026091402101032000_97.10.890.5","unstructured":"The European Medicines Agency\u2019s Pharmacovigilance Risk Assessment Committee (PRAC) . PRAC non-interventional imposed pass final study report assessment report. Available: https:\/\/www.ema.europa.eu\/system\/files\/documents\/other\/emea-h-n-psr-j-0043-epar_en_0.pdf"},{"key":"2026091402101032000_97.10.890.6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.42581","article-title":"Paternal Valproate Use and Neurodevelopmental Disorder and Congenital Malformation Risk in Offspring","volume":"8","author":"Colas","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026091402101032000_97.10.890.7","unstructured":"Medicines and Healthcare products Regulatory Agency . Valproate: review of safety data and expert advice on management of risks. 2023. Available: https:\/\/www.gov.uk\/government\/publications\/valproate-review-of-safety-data-and-expert-advice-on-management-of-risks"},{"key":"2026091402101032000_97.10.890.8","doi-asserted-by":"crossref","DOI":"10.1002\/bdr2.2392","article-title":"Paternal Valproate Treatment and Risk of Childhood Neurodevelopmental Disorders: Precautionary Regulatory Measures Are Insufficiently Substantiated","volume":"116","author":"Garey","year":"2024","journal-title":"Birth Defects Res"},{"key":"2026091402101032000_97.10.890.9","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70016","article-title":"Drifting Too Far From Shore: Paternal Valproate Statement by the European Medicines Agency (EMA)","volume":"33","author":"Damkier","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026091402101032000_97.10.890.10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.14709","article-title":"Valproate Use During Spermatogenesis and Risk to Offspring","volume":"7","author":"Christensen","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026091402101032000_97.10.890.11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.12139","article-title":"Risk of Neurodevelopmental Disorders and Paternal Use of Valproate During Spermatogenesis","volume":"8","author":"Christensen","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026091402101032000_97.10.890.12","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2025-337441"},{"key":"2026091402101032000_97.10.890.13","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2500254","article-title":"Valproate Use by Fathers and Risk of Neurodevelopmental Disorders in Children","volume":"5","author":"Meng","year":"2026","journal-title":"NEJM Evid"},{"key":"2026091402101032000_97.10.890.14","unstructured":"The European Medicines Agency\u2019s Pharmacovigilance Risk Assessment Committee (PRAC). Meeting Highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7\u2013 10 July 2025. Available: https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-7-10-july-2025"},{"key":"2026091402101032000_97.10.890.15","unstructured":"PaTernal exposure to vAlproate, further iNvestiGation on the risk of NeuroDevelopmental Disorders (NDD) and Major Congenital Malformation (MCM) in Offspring: A Non-Interventional Post-Authorization Safety Study (TANGO). Available: https:\/\/catalogues.ema.europa.eu\/node\/4610\/data-management"},{"key":"2026091402101032000_97.10.890.16","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1093\/brain\/awae128","article-title":"Morbidity and mortality risks associated with valproate withdrawal in young adults with epilepsy","volume":"147","author":"Mbizvo","year":"2024","journal-title":"Brain (Bacau)"},{"key":"2026091402101032000_97.10.890.17","unstructured":"Botton J , Rios P , Drouin J , et al . Dray-Spira Rosemary Exposition paternelle au valproate au cours de la spermatogen\u00e8se et risque de troubles neuro-d\u00e9veloppementaux chez l\u2019enfant. n.d. Available: https:\/\/www.epi-phare.fr\/app\/uploads\/2025\/11\/EPI-PHARE_valproate_peres_TND_20251106.pdf"},{"key":"2026091402101032000_97.10.890.18","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-079183","article-title":"Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation","volume":"387","author":"Akl","year":"2024","journal-title":"BMJ"},{"key":"2026091402101032000_97.10.890.19","article-title":"PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst Rev"},{"key":"2026091402101032000_97.10.890.20","unstructured":"metagen: Generic inverse variance meta-analysis. Available: https:\/\/www.rdocumentation.org\/packages\/meta\/versions\/4.9-6\/topics\/metagen"},{"key":"2026091402101032000_97.10.890.21","doi-asserted-by":"crossref","DOI":"10.2196\/64016","article-title":"MetaAnalysisOnline.com: Web-Based Tool for the Rapid Meta-Analysis of Clinical and Epidemiological Studies","volume":"27","author":"Fekete","year":"2025","journal-title":"J Med Internet Res"},{"key":"2026091402101032000_97.10.890.22","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-334077"},{"key":"2026091402101032000_97.10.890.23","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323028"},{"key":"2026091402101032000_97.10.890.24","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12226"},{"key":"2026091402101032000_97.10.890.25","doi-asserted-by":"crossref","first-page":"39033","DOI":"10.1038\/s41598-025-23377-1","article-title":"Paternal valproate use and impact of shared genetic susceptibility on child neurodevelopment","volume":"15","author":"Olstad","year":"2025","journal-title":"Sci Rep"},{"key":"2026091402101032000_97.10.890.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2007.06.012"},{"key":"2026091402101032000_97.10.890.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2022.06.010"},{"key":"2026091402101032000_97.10.890.28","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17057"},{"key":"2026091402101032000_97.10.890.29","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-334547"},{"key":"2026091402101032000_97.10.890.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60461-9"},{"key":"2026091402101032000_97.10.890.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00246-4"},{"key":"2026091402101032000_97.10.890.32","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac042"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2026-338454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:10:50Z","timestamp":1789377050000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2026-338454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,14]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/jnnp-2026-338454"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2026-338454","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]}}}